MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, INDV had -$124M decrease in cash & cash equivalents over the period. -$93M in free cash flow.

Cash Flow Overview

Change in Cash
-$124M
Free Cash flow
-$93M
Unit: Million (M) dollars
Positive Cash Flow Breakdown
    • Net income (loss)
    • Other current and noncurrent ass...
    • Other current and noncurrent lia...
    • Others
Negative Cash Flow Breakdown
    • Accrued legal and settlement exp...
    • Purchases of property and equipm...
    • Deferred income taxes
    • Others

Cash Flow
2025-12-31
2024-12-31
Net income (loss)
210 2
Depreciation and amortization
10 29
Amortization of right-of-use assets
10 -
Stock-based compensation expense
26 24
Impairment of tangible and intangible assets
19 8
Unrealized loss on equity investments
0 -9
Deferred income taxes
-46 6
Acquired in-process research and development
0 1
Impact from foreign exchange movements
-1 2
Other adjustments, net
-0
Accounts receivable
-3 1
Current inventories
-18 45
Other current and noncurrent assets
-49 -378
Accounts payable
-0
Accrued legal and settlement expenses
-368 -387
Other current and noncurrent liabilities
41 14
Net cash (used in) provided by operating activities
-27 36
Purchases of property and equipment
66 29
Purchases of in-process research and development and intangible assets
1 2
Acquisitions, net of cash acquired
0 0
Purchases of investments in debt securities
20 17
Sales of equity securities
1 -
Sales and maturities of debt securities
19 117
Other proceeds from investing activities
0 0
Net cash (used in) provided by investing activities
-66 69
Proceeds from the issuance of common stock
2 3
Cash paid for repurchases of common stock
11 173
Proceeds from debt, net
0 332
Repayments of debt
17 240
Other
--2
Transaction costs related to debt refinancing
0 -
Settlement of tax on equity awards
5 22
Net cash used in financing activities
-30 -102
Net (decrease) increase in cash and cash equivalents
-124 3
Exchange differences
-1 -
Cash and cash equivalents at beginning of period
319 316
Cash and cash equivalents at end of period
195 319
Unit: Million (M) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Net (decrease)increase in cash and cash...-$124M (-4233.33%↓ Y/Y)Sales and maturitiesof debt securities$19M (-83.76%↓ Y/Y)Sales of equitysecurities$1M Proceeds from theissuance of common stock$2M (-33.33%↓ Y/Y)Net income (loss)$210M (10400.00%↑ Y/Y)Other current andnoncurrent assets-$49M (87.04%↑ Y/Y)Other current andnoncurrent liabilities$41M (192.86%↑ Y/Y)Stock-based compensationexpense$26M (8.33%↑ Y/Y)Impairment of tangible andintangible assets$19M (137.50%↑ Y/Y)Current inventories-$18M (-140.00%↓ Y/Y)Amortization of right-of-useassets$10M Depreciation andamortization$10M (-65.52%↓ Y/Y)Accounts receivable-$3M (-400.00%↓ Y/Y)Impact from foreignexchange movements-$1M (-150.00%↓ Y/Y)Net cash (used in)provided by investing...-$66M (-195.65%↓ Y/Y)Net cash used infinancing activities-$30M (70.59%↑ Y/Y)Net cash (used in)provided by operating...-$27M (-175.00%↓ Y/Y)Canceled cashflow$20M Canceled cashflow$2M Canceled cashflow$387M Purchases of property andequipment$66M (127.59%↑ Y/Y)Repayments of debt$17M (-92.92%↓ Y/Y)Cash paid forrepurchases of common stock$11M (-93.64%↓ Y/Y)Settlement of tax on equityawards$5M (-77.27%↓ Y/Y)Accrued legal andsettlement expenses-$368M (4.91%↑ Y/Y)Purchases of investmentsin debt securities$20M (17.65%↑ Y/Y)Deferred income taxes-$46M (-866.67%↓ Y/Y)

indivior-logo-svg

Indivior Pharmaceuticals, Inc. (INDV)

indivior-logo-svg

Indivior Pharmaceuticals, Inc. (INDV)